VXRT · Vaxart, Inc. · Executive Compensation
$0.32
+0.00 (+0.00%)
At close · Jul 8
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In the second quarter of 2026, management concluded that our cash, cash equivalents and investments are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our financial statements, and these conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$126.27M
Shares
243.70M
Volume · Jul 8
11.57M
Avg daily vol (3M)
4.77M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Steven Lo | President and Chief Executive Officer | $2,085,768 |
| Andrei Floroiu | CEO | $1,931,356 |
| James Cummings | Chief Medical Officer | $1,212,535 |
| Sean Tucker | Chief Scientific Officer | $1,155,031 |
| Michael J. Finney | Former Interim Chief Executive Officer | $305,390 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | Former President and Chief Executive Officer | $1,866,844 |
| James Cummings | Chief Medical Officer | $1,174,934 |
| Sean Tucker | Chief Scientific Officer | $1,137,485 |
| Michael Finney | CEO | — |
| Steven Lo | President and Chief Executive Officer | — |
| Michael J. Finney | Former Interim Chief Executive Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | Former President and Chief Executive Officer | $3,589,392 |
| James Cummings | Chief Medical Officer | $1,934,123 |
| Sean Tucker | Chief Scientific Officer | $1,888,689 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | President and Chief Executive Officer | $2,410,175 |
| James Cummings | Chief Medical Officer | $2,379,993 |
| Sean Tucker | Senior Vice President and Chief Scientific Officer | $1,189,150 |
| Margaret A. Echerd | Senior Vice President and Principal Accounting Officer | $1,158,366 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Andrei Floroiu | President and Chief Executive Officer | $2,362,742 |
| Sean Tucker | Senior Vice President and Chief Scientific Officer | $1,224,008 |
| Margaret A. Echerd | Senior Vice President and Principal Accounting Officer | $1,129,695 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Wouter Latour | President and Chief Executive Officer | $747,711 |
| Sean Tucker | Senior Vice President and Chief Scientific Officer | $444,698 |
| Margaret A. Echerd | Senior Vice President and Principal Accounting Officer | $328,952 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Wouter Latour | President and Chief Executive Officer | $850,412 |
| Sean Tucker | Chief Scientific Officer | $378,008 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Raquel C. Bono, M.D., M.B.A., FACS | member of the Board | Appointed | 2026-10-19 |
| James B. Breitmeyer, M.D., Ph.D. | member of the Board | Appointed | 2026-04-23 |
| Michael J. Finney, Ph.D. | Chair of the Board | Retired | 2025-09-02 |
| Jeroen Grasman | Principal Accounting Officer and Principal Financial Officer | Appointed | 2025-05-13 |
| Jeroen Grasman | Chief Financial Officer | Appointed | 2025-05-13 |
| Robert A. Yedid | the Board | Resigned | 2025-01-28 |
| Elaine J. Heron, Ph.D. | member of the Compensation Committee of the Board | Appointed | 2025-01-28 |
| Kevin Finney | member of the Board of Directors | Appointed | 2025-01-28 |
| Robert A. Yedid | Director | Appointed | 2024-06-13 |
| David Wheadon, M.D. | Director | Appointed | 2024-06-13 |
| Steven Lo | Director | Appointed | 2024-06-13 |
| Elaine J. Heron, Ph.D. | Director | Appointed | 2024-06-13 |
| W. Mark Watson, C.P.A. | Director | Appointed | 2024-06-13 |
| Michael J. Finney, Ph.D. | Director | Appointed | 2024-06-13 |
| Steven Lo | member of the Board | Appointed | 2024-03-06 |
| Michael J. Finney, Ph.D. | Interim President and Chief Executive Officer | Resigned | 2024-03-06 |
| Steven Lo | President | Appointed | 2024-03-06 |
| Steven Lo | Chief Executive Officer | Appointed | 2024-03-06 |
| David Wheadon | Lead Director | Appointed | 2024-01-16 |
| Michael J. Finney | Interim Chief Executive Officer | Appointed | 2024-01-16 |
| Andrei Floroiu | Member of the Board of Directors | Resigned | 2024-01-16 |
| Andrei Floroiu | President and Chief Executive Officer | Resigned | 2024-01-16 |
| Phillip E. Lee | Principal Accounting Officer | Appointed | 2022-12-19 |
| Phillip E. Lee | Chief Financial Officer | Appointed | 2022-12-19 |
| W. Mark Watson | member of the Compensation Committee | Appointed | 2022-08-25 |
Leadership
- Andrei Floroiu CEO
- Michael Finney CEO
- Michael J. Finney CEO, Board Member
- Steven Lo CEO, Board Member
- Fuad Ahmad CFO
- Phillip E. Lee CFO, Chief Accounting Officer
- Edward Berg General Counsel
- Jeroen Grasman Chief Accounting Officer
- David Wheadon Board Member
- David Wheadon, M.D. Board Member
- Elaine J. Heron Board Member
- Elaine J. Heron, Ph.D. Board Member
- James B. Breitmeyer, M.D., Ph.D. Board Member
- Julie M. Cherrington, Ph.D. Board Member
- Keith Maher, M.D. Board Member
- Kevin Finney Board Member
- Kevin P. Finney Board Member
- Michael J. Finney, Ph.D. Board Member
- Raquel C. Bono, M.D., M.B.A., FACS Board Member
- Robert A. Yedid Board Member
- Steven Boyd Board Member
- Todd C. Davis Board Member
- W. Mark Watson Board Member
- W. Mark Watson, C.P.A. Board Member
- Wouter Latour, M.D. Board Member